$VBIO News

Valion Bio To Carry Out Study At Sheba Medical Center To Mull Entolimod In 10 Cancer Participants

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

Valion Bio Announces That The Pentagon's Armed Forces Radiobiology Research Institute And National Institute of Allergy and Infectious Diseases Completed Their Design Of Survival Efficacy Protocol To Evaluate The Company's Entolimod To Treat Gastrointestinal Acute Radiation Syndrome

Valion Bio Issues $250K Series Securities Under Its April 29, 2025 Securities Purchase Agreement With Undisclosed Investor

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures

Valion Bio Confirms That A House Armed Services Committee Report Directs The Pentagon To Plan For Prioritizing Radiation And Nuclear Countermeasures

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME

Valion Bio Advances U.S. Department Of War And BARDA Engagement On Entolimod Radiation Countermeasure; Highlights Interest In Oral Formulation For Field Deployment And National Stockpiles

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform

VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Valion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks Transcript

Valion Bio Q1 2026 Earnings Call: Complete Transcript

Valion Bio's Velocity Bioworks Enters Into Exclusive Commercial Development And License Agreement With LarmorBio For BioScan-NMR Platform

Valion Bio Q1 EPS $(2.23) Up From $(2.52) YoY

Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION

Valion Bio Receives First Study Protocol Under Non-Clinical Evaluation Agreement With National Institute Of Allergy And Infectious Diseases; NIAID To Fully Fund In Vivo Studies Required To Support BLA For Entolimod Under FDA's Animal Rule Pathway

VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME

Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening